Friedberg reports Altos Labs raised $3 billion from Bezos and others to recruit academic research teams.
“And they've been going out and just grabbing some of the best academic and research teams out there that are like, they brought a ton of people out from UCSF.”
Friedberg cites recent Harvard research showing aging may be driven by epigenome dysfunction rather than DNA mutations.
“And increasingly, there's evidence as published a few weeks ago in two different papers, including one out of led by a team out of Harvard, that it may be dysfunctions not in the genome and the DNA, but actually dysfunctions in the epigenome, which is the molecules that sit on the DNA.”
Friedberg states age reversal cocktails are currently in human clinical trials with positive in vitro results.
“Way less than that. Way less than that. We are in clinical trials now on several of these cocktails.”
Friedberg states extending lifespan by one year adds tens of trillions to GDP.
“For every one year, we can extend average human lifespan. We're adding tens of trillions of dollars to GDP. Right? So this is also another big economic driver.”
Friedberg reports longevity cocktails are already in clinical trials with human cells tested in vitro.
“And if there's always a risk in going from animals to humans, but we've done it with human cells in in vitro, in a in a petri dish,”
Friedberg explains Yamanaka factors are first targeting specific diseases like blindness before systemic treatment.
“They're starting with targeting diseases, like a particular like like blindness or glaucoma in the eye or, you know, rheumatoid arthritis or some other heart issue, and they're applying these factors to the cells in that tissue only.”
Friedberg explains that partial application of Yamanaka factors can reverse aging in cells without converting them to stem cells.
“In 2016, another scientist published a series of papers showing that instead of putting a lot of those four proteins on the cell, you could put a small amount.”